TY - JOUR
T1 - Humoral immune mechanisms involved in protective and pathological immunity during COVID-19
AU - Widjaja, Gunawan
AU - Turki Jalil, Abduladheem
AU - Sulaiman Rahman, Heshu
AU - Abdelbasset, Walid Kamal
AU - Bokov, Dmitry O.
AU - Suksatan, Wanich
AU - Ghaebi, Mahnaz
AU - Marofi, Faroogh
AU - Gholizadeh Navashenaq, Jamshid
AU - Jadidi-Niaragh, Farhad
AU - Ahmadi, Majid
N1 - Publisher Copyright:
© 2021 American Society for Histocompatibility and Immunogenetics
PY - 2021/10
Y1 - 2021/10
N2 - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 is associated with excessive inflammation, as a main reason for severe condition and death. Increased inflammatory cytokines and humoral response to SARS-CoV-2 correlate with COVID-19 immunity and pathogenesis. Importantly, the levels of pro-inflammatory cytokines that increase profoundly in systemic circulation appear as part of the clinical pictures of two overlapping conditions, sepsis and the hemophagocytic syndromes. Both conditions can develop lethal inflammatory responses that lead to tissue damage, however, in many patients hemophagocytic lymphohistiocytosis (HLH) can be differentiated from sepsis. This is a key issue because the life-saving aggressive immunosuppressive treatment, required in the HLH therapy, is absent in sepsis guidelines. This paper aims to describe the pathophysiology and clinical relevance of these distinct entities in the course of COVID-19 that resemble sepsis and further highlights two effector arms of the humoral immune response (inflammatory cytokine and immunoglobulin production) during COVID-19 infection.
AB - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 is associated with excessive inflammation, as a main reason for severe condition and death. Increased inflammatory cytokines and humoral response to SARS-CoV-2 correlate with COVID-19 immunity and pathogenesis. Importantly, the levels of pro-inflammatory cytokines that increase profoundly in systemic circulation appear as part of the clinical pictures of two overlapping conditions, sepsis and the hemophagocytic syndromes. Both conditions can develop lethal inflammatory responses that lead to tissue damage, however, in many patients hemophagocytic lymphohistiocytosis (HLH) can be differentiated from sepsis. This is a key issue because the life-saving aggressive immunosuppressive treatment, required in the HLH therapy, is absent in sepsis guidelines. This paper aims to describe the pathophysiology and clinical relevance of these distinct entities in the course of COVID-19 that resemble sepsis and further highlights two effector arms of the humoral immune response (inflammatory cytokine and immunoglobulin production) during COVID-19 infection.
KW - 2019 novel coronavirus disease (COVID-19)
KW - Antibody response
KW - Hemophagocytic lymphohistiocytosis (HLH)
KW - Sepsis
KW - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
UR - http://www.scopus.com/inward/record.url?scp=85110143901&partnerID=8YFLogxK
U2 - 10.1016/j.humimm.2021.06.011
DO - 10.1016/j.humimm.2021.06.011
M3 - Review article
C2 - 34229864
AN - SCOPUS:85110143901
SN - 0198-8859
VL - 82
SP - 733
EP - 745
JO - Human Immunology
JF - Human Immunology
IS - 10
ER -